A detailed history of Gamma Investing LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Gamma Investing LLC holds 552 shares of PTGX stock, worth $26,286. This represents 0.0% of its overall portfolio holdings.

Number of Shares
552
Previous 65 749.23%
Holding current value
$26,286
Previous $2.25 Million 1003.02%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$33.72 - $47.33 $16,421 - $23,049
487 Added 749.23%
552 $24.8 Million
Q2 2024

Jul 02, 2024

BUY
$24.66 - $34.8 $419 - $591
17 Added 35.42%
65 $2.25 Million
Q1 2024

Apr 05, 2024

BUY
$21.79 - $32.15 $501 - $739
23 Added 92.0%
48 $1.39 Million
Q4 2023

Feb 01, 2024

BUY
$14.05 - $23.44 $351 - $586
25 New
25 $625,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Gamma Investing LLC Portfolio

Follow Gamma Investing LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gamma Investing LLC with notifications on news.